Business Context and Reporting Period
This Form 8-K filing by Prestige Consumer Healthcare Inc. (PBH) is dated January 6, 2025. The report discloses a significant executive leadership change within the company's principal officers.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
Executive Appointment: Christine Sacco, previously the Chief Financial Officer (CFO) since September 2016, has been appointed as the Chief Operating Officer (COO), effective January 6, 2025. She will retain her role as CFO.
Compensation Adjustments: In connection with the expanded role, Ms. Sacco's compensation package has been updated as follows:
- Base Salary: $700,000 annually.
- Cash Incentive: Target annual cash incentive of 75% of base salary.
- Long-Term Equity Awards: Targeted award value of $1,575,000, allocated 60% to performance stock units and 40% to restricted stock units.
- Retention Award: A time-based restricted stock unit (RSU) award with an aggregate value of $1,575,000. These RSUs cliff vest in full four years after the grant date, subject to continued employment.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, outlook, or management commentary regarding future business performance. No new risks or contingencies are disclosed in this report. The filing confirms there are no family relationships between Ms. Sacco and any director or officer, and no other arrangements requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the impact of the dual CFO/COO role on the company's operational and financial reporting structure.
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Monitor future filings for the appointment of a successor to the CFO role if Ms. Sacco's focus shifts primarily to operations.
- Assess the dilution impact of the $1,575,000 retention award and annual equity targets on existing shareholders.